International Penile Advanced Cancer Trial (International Rare Cancers Initiative Study)

• Status: Recruiting
• Trial end date: 2022-07-01
• Target enrollment: 0
• Participant gender: Male

Summary

This is an international phase III trial, with a Bayesian design, incorporating two sequential randomisations. It efficiently examines a series of questions that routinely arise in the sequencing of treatment. The study design has evolved from lengthy international consultation that has enabled us to build consensus over which questions arise from current knowledge and practice. It will enable potential randomisation for the majority of patients with inguinal lymph node metastases and will provide data to inform future clinical decisions.

InPACT-neoadjuvant patients are stratified by disease burden as assessed by radiological criteria. Treatment options are then defined according to the disease burden strata. Treatment is allocated by randomisation. Patients may be allocated to one of three initial treatments:

A. standard surgery (ILND); B. neoadjuvant chemotherapy followed by standard surgery (ILND); or C. neoadjuvant chemoradiotherapy followed by standard surgery (ILND).

After ILND, patients are defined as being at low or high risk of recurrence based on histological interpretation of the ILND specimen. Patients at high risk of relapse are eligible for InPACT-pelvis, where they are randomised to either:

P. prophylactic PLND Q. no prophylactic PLND

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Institute of Cancer Research, United Kingdom
• Collaborators: Canadian Cancer Trials Group; ECOG-ACRIN Cancer Research Group; European Organisation for Research and Treatment of Cancer - EORTC; National Cancer Institute (NCI)
• Treatments: Albumin-Bound Paclitaxel; Cisplatin; Ifosfamide; Isophosphamide mustard; Paclitaxel

Criteria

Inclusion Criteria:

1. Written informed consent

2. Measurable disease as determined by RECIST (version 1.1) criteria;

3. Histologically-proven squamous cell carcinoma of the penis,

4. Stage:

• any T, N1 (i.e. a palpable mobile unilateral inguinal lymph node), M0 or;

• any T, N2 (i.e. palpable mobile multiple or bilateral inguinal lymph nodes), M0 or;

• any T, N3 (i.e. fixed inguinal nodal mass or any pelvic lymphadenopathy), M0

5. Performance Status ECOG 0, 1 or 2.

Exclusion Criteria:

1. Pure verrucous carcinoma of the penis,

2. Nonsquamous malignancy of the penis,

3. Squamous carcinoma of the urethra,

4. Stage M1,

5. Previous chemotherapy or chemoradiotherapy,

6. Concurrent malignancy (other than SCC or Basal Cell Carcinoma of non-penile skin) that has required surgical or non-surgical treatment in the last 3 years.